

June 24, 2025

Company name Japan Medical Dynamic Marketing, INC.
 Name of representative Toshiyuki Hironaka
 Representative Director and President
 (Securities code: 7600 ;
 Tokyo Stock Exchange Prime)
 Inquiries Shinji Munechika General Manager,
 Investor Relations Office
 Telephone: +81-3-3341-6705

Matters Concerning Controlling Shareholders, etc.

We hereby announce that the matters concerning the controlling shareholder, etc., of our other affiliated company, Mitsui Chemicals, Inc.

1. Parent company, controlling shareholder (excluding the parent company) or other related company's trade name, etc.

(As of March 31, 2025)

Company Name	Attribution	Voting rights ownership ratio (%)			Stock certificates issued are listed on Financial Instruments Exchange
		Direct ownership	Amount to be added	Total	
Mitsui Chemicals, Inc.	Other affiliated companies	30.01	0	30.01	Tokyo Stock Exchange, TSE Prime Market

2. Position of the listed company in the corporate group of the parent company, etc. and other relationships between the listed company and the parent company, etc.

Our Company and Mitsui Chemicals, Inc. have entered into a capital and business alliance with the aim of further expanding their businesses by effectively utilizing the management resources of both companies, achieving sustainable growth of the Company and Mitsui Chemicals Group in the medical device field, and enhancing the corporate value of both groups.

Mitsui Chemicals, Inc. is an affiliate (other affiliate) of the Company owning 30.01% of the Company's voting rights. In addition, the Company has no particular restrictions from the Mitsui Chemicals, Inc. group, such as approval items, in conducting its business activities.

(Status of concurrent directorships)

(As of June 24, 2025)

position	name	Position in parent company or its group companies	Reason for appointment
Outside Director	Tomoyuki Okamura	Mitsui Chemicals, Inc. General Manager, Medical Business Development Office, Life & Healthcare Solutions Business Division	To supervise the Company's management from the standpoint of an outside director

3. Status of Securing a Certain Level of Independence from Parent Company, etc.

Our Company recognizes that there are no factors that would hinder its free business activities from the Mitsui Chemicals Group, and believes that it is in a position to make independent business judgments. The appointment of directors does not hinder independent business judgment, and a certain degree of independence is ensured.

4. Transactions with Controlling Shareholders (From April 1, 2024 to March 31, 2025)

There are no applicable matters.

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.